Oppenheimer Maintains an 'Outperform' on Immunogen Inc. (IMGN); Advancing NORTH
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
ImmunoGen (IMGN) Reports Encouraging Data from NORTH Trial Phase II on SCLC
September 6, 2012 8:47 AM EDTImmunoGen, Inc. (Nasdaq: IMGN) announced the presentation of clinical data for the Companys IMGN901 targeted anticancer compound at the Chicago Multidisciplinary Symposium in Thoracic Oncology.
This Phase I assessment was designed to establish the dose of IMGN901 to be used in combination with etoposide (E) and carboplatin (C) in a Phase II assessment the NORTH trial of this combination regimen for the first-line treatment of SCLC. E/C is a standard treatment for newly diagnosed, extensive disease SCLC, and the NORTH trial is designed to assess whether adding IMGN901 to E/C provides a... More
